Autifony Therapeutics
Autifony Therapeutics develops small molecule drugs targeting the Kv3 family of potassium channels to treat rare central nervous system (CNS) disorders. Its clinical-stage pipeline includes AUT00206 for Fragile X syndrome and AUT00201 for rare epilepsy syndromes. The company also researches treatments for schizophrenia, age-related hearing loss, and neurodegenerative disorders using its ion channel platform.
Biotechnology
Healthcare
Pharmaceuticals
CNS Disorders
Funding summary
- Total raised
- €10.0M
- Funding rounds
- 2
Investors in Autifony Therapeutics
Investors on record for Autifony Therapeutics. Click any investor to view their CAPLINK profile and funding criteria.
Fundraising for a startup like Autifony Therapeutics?
Explore CAPLINK's investor database of thousands of active VCs and angels.
Browse investors